Role of melanocortins in the central control of feeding.

The injection of a melanocortin peptide or of melanocortin peptide analogues into the cerebrospinal fluid or into the ventromedial hypothalamus in nanomolar or subnanomolar doses induces a long-lasting inhibition of food intake. The effect keeps significant for up to 9 h and has been observed in all animal species so far tested, the most susceptible being the rabbit. The anorectic effect of these peptides is a primary one, not secondary to the shift towards other components of the complex melanocortin-induced behavioral syndrome, in particular grooming. The site of action is in the brain, and the effect is not adrenal-mediated because it is fully exhibited also by adrenalectomized animals. It is a very strong effect, because the degree of feeding inhibition is not reduced in conditions of hunger, either induced by 24 h starvation, or by insulin-induced hypoglycemia, or by stimulation of gamma-aminobutyric acid (GABA), noradrenergic or opioid systems. The microstructural analysis of feeding behavior suggests that melanocortins act as satiety-inducing agents, because they do not significantly modify the latencies to start eating, but shorten the latencies to stop eating. The mechanism of action involves the activation of melanocortin MC(4) receptors, because selective melanocortin MC(4) receptor antagonists inhibit the anorectic effect of melanocortins, while inducing per se a strong stimulation of food intake and a significant increase in body weight. Melanocortins seem to play an important role in stress-induced anorexia, because such condition, in rats, is significantly attenuated by the blockage of melanocortin MC(4) receptors; such a role is not secondary to an increased release of corticotropin-releasing factor (CRF), because, on the other hand, the CRF-induced anorexia is not affected at all by the blockage of melanocortin MC(4) receptors. The physiological meaning of the feeding inhibitory effect of melanocortins, and, by consequence, the physiological role of melanocortins in the complex machinery responsible for body weight homeostasis, is testified by the hyperphagia/obesity syndromes caused by mutations in the pro-opiomelanocortin (POMC) gene, or in the melanocortin MC(4) receptor gene, or in the agouti locus. Finally, recent evidences suggest that melanocortins could be involved in mediating the effects of leptin, and in controlling the expression of neuropeptide Y (NPY).

[1]  J. Flier Leptin expression and action: new experimental paradigms. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[2]  A. Vergoni,et al.  Cross‐Species Comparison of the ACTH‐induced Behavioral Syndrome , 1988, Annals of the New York Academy of Sciences.

[3]  P. Prusis,et al.  Long term orexigenic effect of a novel melanocortin 4 receptor selective antagonist , 1999, British journal of pharmacology.

[4]  G. Gessa,et al.  ACTH-(1-24) antagonizes the contractile effect of morphine on the isolated rat colon. , 1985, European journal of pharmacology.

[5]  D. Wied,et al.  Central actions of ACTH and related peptides , 1986 .

[6]  G. Gessa,et al.  Sexual Behavior: Pharmacology and Biochemistry , 1975 .

[7]  M. Castelli,et al.  ACTH-(1-24) antagonizes the cholestatic and constipating effects of morphine. , 1988, Archives internationales de pharmacodynamie et de therapie.

[8]  J. Wikberg,et al.  Selective antagonist for the melanocortin 4 receptor (HS014) increases food intake in free-feeding rats. , 1998, Biochemical and biophysical research communications.

[9]  R. Duman,et al.  Melanocortins and opiate addiction. , 1997, Life sciences.

[10]  K. Clément,et al.  A frameshift mutation in human MC4R is associated with a dominant form of obesity , 1998, Nature Genetics.

[11]  T. O'donohue,et al.  The opiomelanotropinergic neuronal and endocrine systems , 1982, Peptides.

[12]  V. Hruby,et al.  Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study. , 1998, The Journal of urology.

[13]  R. Samanin,et al.  The hypophagic effect of restraint stress in rats can be mediated by 5-HT2 receptors in the paraventricular nucleus of the hypothalamus , 1993, Neuroscience Letters.

[14]  R. Seeley,et al.  Melanocortin receptors in leptin effects , 1997, Nature.

[15]  J. Blundell,et al.  Pharmacology of Eating Disorders: Theoretical and Clinical Developments , 1986 .

[16]  K. Nakao,et al.  Satiety effect and sympathetic activation of leptin are mediated by hypothalamic melanocortin system , 1998, Neuroscience Letters.

[17]  G. Gessa,et al.  Hypothalamic ACTH and MSH levels increase in morphine tolerance and decrease after morphine withdrawal. , 1983, European journal of pharmacology.

[18]  S. Woods,et al.  Leptin Increases Hypothalamic Pro-opiomelanocortin mRNA Expression in the Rostral Arcuate Nucleus , 1997, Diabetes.

[19]  Joyce Slochower,et al.  Emotional Labeling and Overeating in Obese and Normal Weight Individuals , 1976, Psychosomatic medicine.

[20]  E. Endrőczi,et al.  Neuropeptides and psychosomatic processes , 1983 .

[21]  S. Guarini,et al.  The adrenocorticotropic hormone (ACTH)-induced reversal of hemorrhagic shock. , 1989, Resuscitation.

[22]  L. Stubbs,et al.  A molecular model for the genetic and phenotypic characteristics of the mouse lethal yellow (Ay) mutation. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[23]  S. Guarini,et al.  Evidence that melanocortins are physiological antagonists of opioids , 1986 .

[24]  J. Wikberg,et al.  Molecular cloning of a novel human melanocortin receptor. , 1993, Biochemical and biophysical research communications.

[25]  V. Hruby,et al.  Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. , 1996, Life sciences.

[26]  J. Wikberg,et al.  Corticotropin-releasing factor (CRF) induced anorexia is not influenced by a melanocortin 4 receptor blockage , 1999, Peptides.

[27]  A. Vergoni,et al.  ACTH-(1–24) and α-MSH antagonize feeding behavior stimulated by kappa opiate agonists , 1986, Peptides.

[28]  W. Ferrari Behavioural Changes in Animals after Intracisternal Injection with Adrenocorticotrophic Hormone and Melanocyte-Stimulating Hormone , 1958, Nature.

[29]  W. Fratta,et al.  Reciprocal antagonism between ACTH1–24 and β-endorphin in rats , 1981, Neuroscience Letters.

[30]  F. G. Henke,et al.  Mental diagnosis by the association reaction method , 1909 .

[31]  Y. Konda,et al.  Molecular cloning, expression, and characterization of a fifth melanocortin receptor. , 1994, Biochemical and biophysical research communications.

[32]  K. Flegal,et al.  Assessing obesity: classification and epidemiology. , 1997, British medical bulletin.

[33]  G. Gessa,et al.  Induction of Sexual Excitement by the Action of Adrenocorticotrophic Hormone in Brain , 1969, Nature.

[34]  J. Wikberg,et al.  Long-term administration of MC4 receptor antagonist HS014 causes hyperphagia and obesity in rats. , 1999, Neuroreport.

[35]  A. Bertolini The opioid/anti-opioid balance in shock: a new target for therapy in resuscitation. , 1995, Resuscitation.

[36]  J. Wikberg,et al.  Differential influence of a selective melanocortin MC4 receptor antagonist (HS014) on melanocortin-induced behavioral effects in rats. , 1998, European journal of pharmacology.

[37]  Y. Oomura,et al.  Stress-induced anorexia in rats mediated by serotonergic mechanisms in the hypothalamus , 1989, Physiology & Behavior.

[38]  R. Cone,et al.  Induction of neuropeptide Y gene expression in the dorsal medial hypothalamic nucleus in two models of the agouti obesity syndrome. , 1997, Molecular endocrinology.

[39]  J. Burbach,et al.  Identification of antagonists for melanocortin MC3, MC4 and MC5 receptors. , 1994, European journal of pharmacology.

[40]  C. Hendrie Opiate dependence and withdrawal— A new synthesis? , 1985, Pharmacology Biochemistry and Behavior.

[41]  W. Gispen,et al.  ACTH-induced excessive grooming in the rat. , 1981, Pharmacology & therapeutics.

[42]  A. Grüters,et al.  Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans , 1998, Nature Genetics.

[43]  J. Wikberg,et al.  Discovery of a novel superpotent and selective melanocortin-4 receptor antagonist (HS024): evaluation in vitro and in vivo. , 1998, Endocrinology.

[44]  S. O’Rahilly,et al.  A frameshift mutation in MC4R associated with dominantly inherited human obesity , 1998, Nature Genetics.

[45]  G. Gessa,et al.  BEHAVIORAL EFFECTS INDUCED BY INTRACISTERNALLY INJECTED ACTH AND MSH * , 1963, Annals of the New York Academy of Sciences.

[46]  A. Vergoni,et al.  Corticotropin inhibits food intake in rats , 1986, Neuropeptides.

[47]  S. Watson,et al.  Molecular cloning of a novel melanocortin receptor. , 1993, The Journal of biological chemistry.

[48]  N. Ling,et al.  Involvement of corticotropin-releasing factor in restraint stress-induced anorexia and reversion of the anorexia by somatostatin in the rat. , 1988, Life sciences.

[49]  J. Morley,et al.  Stress induced eating , 1983 .

[50]  Victor J. Hruby,et al.  Role of melanocortinergic neurons in feeding and the agouti obesity syndrome , 1997, Nature.

[51]  M. Mortrud,et al.  The cloning of a family of genes that encode the melanocortin receptors. , 1992, Science.

[52]  J. Wikberg,et al.  Melanocortin receptors: perspectives for novel drugs. , 1999, European journal of pharmacology.

[53]  J. Wikberg,et al.  Evidence for involvement of the melanocortin MC4 receptor in the effects of leptin on food intake and body weight. , 1998, European journal of pharmacology.

[54]  J. Blundell,et al.  Dual Action of Naloxone on Feeding Revealed by Behavioural Analysis: Separate Effects on Initiation and Termination of Eating , 1984, Appetite.

[55]  G. Barsh,et al.  Neomorphic agouti mutations in obese yellow mice , 1994, Nature Genetics.

[56]  R. Cone,et al.  Targeted Disruption of the Melanocortin-4 Receptor Results in Obesity in Mice , 1997, Cell.

[57]  Richard P. Woychik,et al.  Agouti protein is an antagonist of the melanocyte-stimulating-hormone receptor , 1994, Nature.

[58]  G. Barsh,et al.  Antagonism of central melanocortin receptors in vitro and in vivo by agouti-related protein. , 1997, Science.

[59]  D. Marrama,et al.  Inhibition of feeding by ACTH-(1-24): behavioral and pharmacological aspects. , 1990, European journal of pharmacology.

[60]  G. Chrousos,et al.  Abnormal hypothalamic-pituitary-adrenal function in anorexia nervosa. Pathophysiologic mechanisms in underweight and weight-corrected patients. , 1986, The New England journal of medicine.

[61]  J. Wikberg,et al.  Molecular cloning and expression of the human melanocyte stimulating hormone receptor cDNA , 1992, FEBS letters.

[62]  C. Mantzoros,et al.  Leptin: in search of role(s) in human physiology and pathophysiology , 1998, Clinical endocrinology.

[63]  Y. Jacquet Opiate effects after adrenocorticotropin or beta-endorphin injection in the periaqueductal gray matter of rats. , 1978, Science.

[64]  J. Treasure,et al.  Psychosocial factors in the onset of eating disorders: responses to life-events and difficulties. , 1997, The British journal of medical psychology.

[65]  M. Feelisch,et al.  Correlation between nitric oxide formation during degradation of organic nitrates and activation of guanylate cyclase. , 1987, European journal of pharmacology.

[66]  J. Wikberg,et al.  Evidence that orexigenic effects of melanocortin 4 receptor antagonist HS014 are mediated by neuropeptide Y. , 1998, Biochemical and biophysical research communications.

[67]  P. Prusis,et al.  Discovery of novel melanocortin4 receptor selective MSH analogues , 1998, British journal of pharmacology.

[68]  T. Donohoe Stress-induced anorexia: implications for anorexia nervosa. , 1984, Life sciences.

[69]  A. Mark,et al.  Interactions between the melanocortin system and leptin in control of sympathetic nerve traffic. , 1999, Hypertension.

[70]  J. Wikberg,et al.  Selective melanocortin MC4 receptor blockage reduces immobilization stress-induced anorexia in rats. , 1999, European journal of pharmacology.

[71]  D. Krahn,et al.  CRF antagonist partially reverses CRF- and stress-induced effects on feeding , 1986, Brain Research Bulletin.

[72]  W. Paré Stress and Consummatory Behavior in the Albino Rat , 1965, Psychological reports.

[73]  N. Ling,et al.  The responses of plasma adrenocorticotropin and cortisol to corticotropin-releasing hormone (CRH) and cerebrospinal fluid immunoreactive CRH in anorexia nervosa patients. , 1986, The Journal of clinical endocrinology and metabolism.